File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Paclitaxel-Eluting Stent Long-Term Outcomes in Percutaneous Saphenous Vein Graft Interventions (PELOPS) Study

TitlePaclitaxel-Eluting Stent Long-Term Outcomes in Percutaneous Saphenous Vein Graft Interventions (PELOPS) Study
Authors
Issue Date2009
PublisherExcerpta Medica, Inc.. The Journal's web site is located at http://www.ajconline.org/
Citation
American Journal Of Cardiology, 2009, v. 103 n. 2, p. 199-202 How to Cite?
AbstractThis study examined the 1-year clinical and angiographic follow-up results of implantation of paclitaxel-eluting stents (PES) in aortocoronary saphenous vein graft (SVG) lesions. Sixty-eight consecutive patients with 90 nonoccluded SVG lesions were treated with PES (Taxus), size ranging from 2.25 to 4.5 mm. Angiographic follow-up was performed on 63 patients (93%) and 83 lesions (92%) at 12 months; major adverse cardiac event (MACE) was recorded in all patients at 1 year. The mean age of patients was 71 ± 8 years with predominance of men (75%); the mean graft age was 13 ± 4 years. Glycoprotein IIb/ IIIa inhibitors were given in 21 patients (31%); embolic protection devices were used in 54 lesions (60%). On average, patients received 1.4 stents per lesion with a stent size of 3.4 ± 0.6 mm and a length of 35.8 ± 27.0 mm. Angiographic follow-up revealed a late loss of 0.36 ± 0.66 mm with an in-segment binary restenosis rate of 7%. The in-hospital MACE was 7%, which was solely contributed by 5 patients with postprocedure non-Q myocardial infarction; the 1-year MACE was 15%, accounted by 1 noncardiac death and 9 patients with target vessel revascularization. Peripheral vascular disease and the use of glycoprotein IIb/ IIIa inhibitors were the independent predictors of MACE at 1 year. In conclusion, implantation of PES to treat degenerative aortocoronary SVG lesions is safe and associated with low late loss, angiographic restenosis, and MACE at 1-year follow-up. © 2009 Elsevier Inc. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/59163
ISSN
2015 Impact Factor: 3.154
2015 SCImago Journal Rankings: 2.063
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorJim, MHen_HK
dc.contributor.authorHo, HHen_HK
dc.contributor.authorKo, RLyen_HK
dc.contributor.authorYiu, KHen_HK
dc.contributor.authorSiu, CWen_HK
dc.contributor.authorLau, CPen_HK
dc.contributor.authorChow, WHen_HK
dc.date.accessioned2010-05-31T03:44:06Z-
dc.date.available2010-05-31T03:44:06Z-
dc.date.issued2009en_HK
dc.identifier.citationAmerican Journal Of Cardiology, 2009, v. 103 n. 2, p. 199-202en_HK
dc.identifier.issn0002-9149en_HK
dc.identifier.urihttp://hdl.handle.net/10722/59163-
dc.description.abstractThis study examined the 1-year clinical and angiographic follow-up results of implantation of paclitaxel-eluting stents (PES) in aortocoronary saphenous vein graft (SVG) lesions. Sixty-eight consecutive patients with 90 nonoccluded SVG lesions were treated with PES (Taxus), size ranging from 2.25 to 4.5 mm. Angiographic follow-up was performed on 63 patients (93%) and 83 lesions (92%) at 12 months; major adverse cardiac event (MACE) was recorded in all patients at 1 year. The mean age of patients was 71 ± 8 years with predominance of men (75%); the mean graft age was 13 ± 4 years. Glycoprotein IIb/ IIIa inhibitors were given in 21 patients (31%); embolic protection devices were used in 54 lesions (60%). On average, patients received 1.4 stents per lesion with a stent size of 3.4 ± 0.6 mm and a length of 35.8 ± 27.0 mm. Angiographic follow-up revealed a late loss of 0.36 ± 0.66 mm with an in-segment binary restenosis rate of 7%. The in-hospital MACE was 7%, which was solely contributed by 5 patients with postprocedure non-Q myocardial infarction; the 1-year MACE was 15%, accounted by 1 noncardiac death and 9 patients with target vessel revascularization. Peripheral vascular disease and the use of glycoprotein IIb/ IIIa inhibitors were the independent predictors of MACE at 1 year. In conclusion, implantation of PES to treat degenerative aortocoronary SVG lesions is safe and associated with low late loss, angiographic restenosis, and MACE at 1-year follow-up. © 2009 Elsevier Inc. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherExcerpta Medica, Inc.. The Journal's web site is located at http://www.ajconline.org/en_HK
dc.relation.ispartofAmerican Journal of Cardiologyen_HK
dc.subject.meshAgeden_HK
dc.subject.meshCoronary Angiographyen_HK
dc.subject.meshCoronary Artery Bypassen_HK
dc.subject.meshCoronary Disease - radiography - therapyen_HK
dc.subject.meshDrug-Eluting Stentsen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLogistic Modelsen_HK
dc.subject.meshMaleen_HK
dc.subject.meshPaclitaxel - administration & dosageen_HK
dc.subject.meshProportional Hazards Modelsen_HK
dc.subject.meshProspective Studiesen_HK
dc.subject.meshSaphenous Vein - transplantationen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.subject.meshTubulin Modulators - administration & dosageen_HK
dc.titlePaclitaxel-Eluting Stent Long-Term Outcomes in Percutaneous Saphenous Vein Graft Interventions (PELOPS) Studyen_HK
dc.typeArticleen_HK
dc.identifier.emailYiu, KH:khkyiu@hku.hken_HK
dc.identifier.emailSiu, CW:cwdsiu@hkucc.hku.hken_HK
dc.identifier.authorityYiu, KH=rp01490en_HK
dc.identifier.authoritySiu, CW=rp00534en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.amjcard.2008.08.057en_HK
dc.identifier.pmid19121436-
dc.identifier.scopuseid_2-s2.0-58149464826en_HK
dc.identifier.hkuros153472en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-58149464826&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume103en_HK
dc.identifier.issue2en_HK
dc.identifier.spage199en_HK
dc.identifier.epage202en_HK
dc.identifier.isiWOS:000262564300010-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridJim, MH=6603860344en_HK
dc.identifier.scopusauthoridHo, HH=7401465369en_HK
dc.identifier.scopusauthoridKo, RLy=15020468300en_HK
dc.identifier.scopusauthoridYiu, KH=35172267800en_HK
dc.identifier.scopusauthoridSiu, CW=7006550690en_HK
dc.identifier.scopusauthoridLau, CP=35275317200en_HK
dc.identifier.scopusauthoridChow, WH=7402281062en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats